20.500.12556/DiRROS-24592 The use of continuous glucose monitoring in people living with obesity, intermediate hyperglycemia or type 2 diabetes A global trend towards increased obesity, intermediate hyperglycemia (previously termed prediabetes) and type 2 diabetes, has prompted a range of international initiatives to proactively raise awareness and provide action-driven recommendations to prevent and manage these linked disease states. One approach, that has shown success in managing people already diagnosed with type 2 diabetes mellitus, is to use continuous glucose monitoring (CGM) devices to help them manage their chronic condition through understanding and treating their daily glucose fluctuations, in assocation with glucose-lowering medications, including insulin. However, much of the burden of type 2 diabetes mellitus is founded in the delayed detection both of type 2 diabetes mellitus itself, and the intermediate hyperglycemia that precedes it. In this review, we provide evidence that using CGM technology in people at-risk of intermediate hyperglycemia or type 2 diabetes mellitus can significantly improve the rate and timing of detection of dysglycemia. Earlier detection allows intervention, including through continued use of CGM to guide changes to diet and lifestyle, that can delay or prevent harmful progression of early dysglycemia. Although further research is needed to fully understand the cost-effectiveness of this intervention in people at-risk or with early dysglycemia, the proposition for use of CGM technology is clear. continuous glucose monitoring consensus statements intermediate hyperglycemia obesity prediabetes true false true Angleški jezik Ni določen Neznano 2025-12-08 14:17:37 2025-12-08 14:17:37 2025-12-09 03:44:02 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 29. 9. 2025; str. 1-12 Vol. 223 2025 0000-00-00 Zaloznikova Objavljeno apc 0000-00-00 0000-00-00 0000-00-00 616.379 1872-8227 10.1016/j.diabres.2025.112111 250818563 RAZ_Battelino_Tadej_2025.pdf RAZ_Battelino_Tadej_2025.pdf 1 18AE24CDE697E16A10868162AD0F42A5 1f588341cc947e0f997bafec24bd653c64f5f619b18dfa94d632b7b88039b5f6 85276cf1-d438-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36696 https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(25)00125-1/fulltext 0 479edc75-d438-11f0-94a7-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=36695 Univerzitetni klinični center Ljubljana 0 0 0